Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis.

Beyar-Katz O, Bitterman R, Zuckerman T, Ofran Y, Yahav D, Paul M.

Clin Microbiol Infect. 2020 Feb;26(2):189-198. doi: 10.1016/j.cmi.2019.09.003. Epub 2019 Sep 16. Review.

PMID:
31536817
2.

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia.

Ofran Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, Yehudai-Ofir D, Henig I, Beyar-Katz O, Hayun M, Frisch A.

Leukemia. 2020 Jan;34(1):293-295. doi: 10.1038/s41375-019-0548-z. Epub 2019 Aug 21. No abstract available.

PMID:
31435023
3.

Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy.

Beyar-Katz O, Magidey K, Reiner-Benaim A, Barak N, Avivi I, Cohen Y, Timaner M, Avraham S, Hayun M, Lavi N, Bersudsky M, Voronov E, Apte RN, Shaked Y.

Mol Cancer Res. 2019 Nov;17(11):2331-2340. doi: 10.1158/1541-7786.MCR-19-0487. Epub 2019 Aug 13.

PMID:
31409628
4.

Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.

Beyar-Katz O, Lavi N, Ringelstein-Harlev S, Henig I, Yehudai-Ofir D, Haddad N, Fineman R, Ofran Y, Nov Y, Sahar D, Moustafa-Hawash N, Rowe JM, Zuckerman T.

Leuk Lymphoma. 2019 Oct;60(10):2449-2456. doi: 10.1080/10428194.2019.1594214. Epub 2019 Apr 3.

PMID:
30943060
5.

Novel Approaches to Acute Myeloid Leukemia Immunotherapy.

Beyar-Katz O, Gill S.

Clin Cancer Res. 2018 Nov 15;24(22):5502-5515. doi: 10.1158/1078-0432.CCR-17-3016. Epub 2018 Jun 14. Review.

6.

Primary Marginal Zone Lymphoma of the Lung and Organizing Pneumonia: A Diagnostic Challenge.

Corina Sela T, Beyar Katz O, Tadmor T, Bejar J, Schiff E.

Isr Med Assoc J. 2018 Mar;20(3):197-198. No abstract available.

7.

Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells.

Timaner M, Letko-Khait N, Kotsofruk R, Benguigui M, Beyar-Katz O, Rachman-Tzemah C, Raviv Z, Bronshtein T, Machluf M, Shaked Y.

Cancer Res. 2018 Mar 1;78(5):1253-1265. doi: 10.1158/0008-5472.CAN-17-1547. Epub 2018 Jan 4.

8.

The Clinical Spectrum of Hepatic Manifestations in Chronic Lymphocytic Leukemia.

Kreiniz N, Beyar Katz O, Polliack A, Tadmor T.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):863-869. doi: 10.1016/j.clml.2017.07.008. Epub 2017 Jul 23. Review.

PMID:
28803824
9.

Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer.

Beyar-Katz O, Dickstein Y, Borok S, Vidal L, Leibovici L, Paul M.

Cochrane Database Syst Rev. 2017 Jun 3;6:CD003914. doi: 10.1002/14651858.CD003914.pub4. Review.

10.

Published abstracts at international meetings often over- or underestimate the initial response rate.

Beyar-Katz O, Rowe JM, Townsend LE, Tallman MS, Hadomi R, Horowitz NA.

Blood. 2017 Apr 20;129(16):2326-2328. doi: 10.1182/blood-2017-01-763144. Epub 2017 Mar 6. No abstract available.

PMID:
28264800
11.

Autoinflammatory associated vasculitis.

Ginsberg S, Rosner I, Rozenbaum M, Slobodin G, Zilber K, Boulman N, Kaly L, Awisat A, Jiries N, Beyar-Katz O, Rimar D.

Semin Arthritis Rheum. 2016 Dec;46(3):367-371. doi: 10.1016/j.semarthrit.2016.07.007. Epub 2016 Jul 20.

PMID:
27612399
12.

Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy.

Shaked Y, Pham E, Hariharan S, Magidey K, Beyar-Katz O, Xu P, Man S, Wu FT, Miller V, Andrews D, Kerbel RS.

Cancer Res. 2016 Oct 15;76(20):5983-5993. Epub 2016 Aug 28.

13.

Peripheral T-cell lymphoma mimicking Schnitzler syndrome.

Beyar Katz O, Schiff E, Rosner I, Tadmor T, Awisat A, Jiries N, Wirsansky I, Ginsberg S.

Int J Rheum Dis. 2017 Dec;20(12):2194-2196. doi: 10.1111/1756-185X.12893. Epub 2016 Jun 20. No abstract available.

PMID:
27321901
14.

Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy.

Beyar-Katz O, Magidey K, Ben-Tsedek N, Alishekevitz D, Timaner M, Miller V, Lindzen M, Yarden Y, Avivi I, Shaked Y.

J Pathol. 2016 Jul;239(3):262-73. doi: 10.1002/path.4723. Epub 2016 Apr 29.

PMID:
27037906
15.

Analysis of the Stromal Cellular Components of the Solid Tumor Microenvironment Using Flow Cytometry.

Timaner M, Beyar-Katz O, Shaked Y.

Curr Protoc Cell Biol. 2016 Mar 1;70:19.18.1-19.18.12. doi: 10.1002/0471143030.cb1918s70.

PMID:
26930555
16.

Should autotransplantation in acute myeloid leukemia in first complete remission be revisited?

Zuckerman T, Beyar-Katz O, Rowe JM.

Curr Opin Hematol. 2016 Mar;23(2):88-94. doi: 10.1097/MOH.0000000000000212. Review.

PMID:
26825697
17.

Nephrotic syndrome after hematopoietic stem cell transplantation: a single center experience.

Beyar Katz O, Kruzel Davila E, Zuckerman T, Fineman R, Haddad N, Okasha D, Henig I, Rowe JM, Ofran Y.

Minerva Med. 2015 Dec;106(6):355-7. No abstract available.

PMID:
26787650
18.

Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to Therapy.

Beyar-Katz O, Davila EK, Zuckerman T, Fineman R, Haddad N, Okasha D, Henig I, Leiba R, Rowe JM, Ofran Y.

Biol Blood Marrow Transplant. 2016 Jun;22(6):975-981. doi: 10.1016/j.bbmt.2015.12.014. Epub 2015 Dec 29. Review.

Supplemental Content

Loading ...
Support Center